Prediction of pCR with pretreatment MRI radiomics in triple negative breast cancer treated with neoadjuvant chemo-immunotherapy.
Toulsie Ramtohul(Université Paris Sciences et Lettres), A. Tardivon(Université Paris Sciences et Lettres), Emmanuelle Menet(Institut Curie), Enora Laas(Institut Curie), Caroline Malhaire(Université Paris Sciences et Lettres), Diana Bello(Institut Curie), Claire Bonneau(Inserm), Luc Cabel(Université de Versailles Saint-Quentin-en-Yvelines), A. Langer(Inserm), Emanuela Romano(Inserm), Victoire Lepagnay(Institut Curie), Juliette Sauge(Inserm), Fatima Mechta-Grigoriou(Inserm), Maxime Jin(Inserm), François‐Clément Bidard(Inserm)
Cited by 2
Related Papers
Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer
|Cancer Cell|2018|1.7k
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
|Journal of Clinical Oncology|2022|676
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
|Proceedings of the National Academy of Sciences|2015|581
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis
|JNCI Journal of the National Cancer Institute|2018|282
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
|Critical Reviews in Oncology/Hematology|2018|268